Organon & Co. (OGN)
Health Care · pharmaceuticals · NYSE
Organon is a global healthcare company dedicated to improving the health of women and providing a diverse portfolio of established brands and biosimilar medicines.
What Organon & Co. does
Organon & Co. is a global healthcare company focused on developing and delivering health solutions through a portfolio of medicines and treatments. The company's business is structured around three primary pillars: women's health, biosimilars, and established brands.
Themes: women's health, biosimilars, established brands
Fundamentals
- Price$13.75 as of 2026-08-21 close
- Market cap$3.6B as of 2026-08-21
- 1-year return+48.2% 2025-08-21 close $9.28 → 2026-08-21 close $13.75
- P/E17.24 as of 2026-08-24
- Net margin+3.4% as of 2026-08-24
- Gross margin+52.7% as of 2026-08-24
- ROE+23.4% as of 2026-08-24
- Debt / equity8.50 as of 2026-08-24
- Revenue growth (YoY)-2.5% as of 2026-08-24
- Revenue CAGR (3y)+0.2% SEC XBRL
- Beta1.55 as of 2026-08-24
- Last reported earnings2026-04-30 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +9.9%; 1-year non-decreasing per-share dividend streak (SEC XBRL).
How OGN compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- indicated dividend yieldtop 10% 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
OGN is not currently in any published Top 10 list. Its scores are below.
Long-term score
43.2 #731 of 987 scored · #42 of 57 in Health Care
Long-term trend 86th (a strong uptrend, with buyers in control) and valuation 63rd (price to earnings 17.6, price to book 3.6); weakest is capital return (11th, consecutive years of dividend increases 1 year).
Short-term score
34.1 #1580 of 1,704 scored · #224 of 240 in Health Care
Trend 64th: a strong uptrend, with buyers in control; catalysts 50th: open-market insider buys in 90 days 11, the analyst consensus rating is unchanged since the prior reading; weakest is volume and participation 25th: trading volume is about normal versus its 30-day average. Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, OGN's dividend was covered by reported results (earnings payout 47%, free-cash-flow payout 16%). This describes past coverage, not a forecast.
- Earnings payout47% dividends / net income
- Free-cash-flow payout16% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Organon & Co. looks technically
Organon & Co. (OGN) is trading 39.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 68 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 60, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 74, in overbought territory (above 70). MACD, a trend-momentum gauge, turned bullish about 7 trading days ago (its momentum flipped positive). It just made a new 20-day high, pushing above its recent trading range. It is trading right at its highest price of the past year (its 52-week high).
Trend
7
| Distance from the 200-day | it is trading 39.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +39.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $13.54 | $13.54 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $9.86 | $9.86 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 51 calendar days ago — the swings before that are what the structure reading is measured on | 51 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 68 trading days ago — a "golden cross", a bullish long-term signal | 68 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 60, with buyers in control | 59.6 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 74, in overbought territory (above 70) | 74.1 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($13.54 to $13.76) — its "stochastic" reading is 95 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 95.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 7 trading days ago (its momentum flipped positive) | 7 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $13.76 | $13.76 |
|---|---|---|
| From the 52-week high | it is trading right at its highest price of the past year (its 52-week high) | -0.1% |
| Above the 52-week low | it is 141.7% above its 52-week low (its lowest price of the past year) | +141.7% |
| Below the 52-week high | it is at or near its highest point of the past year | 0.1% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $39.48 (set on 2022-03-02) | $39.48 |
| Given back of the 52-week move | over the past year its closes ranged ($5.70 to $13.75), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $8.52 to $8.78. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 65.2% below its all-time high | -65.2% |
| Nearest price level | it is trading 2.6% above a support level at $13.39 — a price it turned at five times since 2025-04-29, most recently on 2026-07-08. Since 2024-08-21 it has 7 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.6% |
| All-time low | its lowest closing price on record is $5.69 (set on 2026-03-30) | $5.69 |
| Above the all-time low | it is 141.7% above its all-time low | +141.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 47th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.0458 between its high and its low — about 0.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.0458 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $13.47 and $13.78 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $13.47 – $13.63 – $13.78 |
| Typical daily range (% of price) | its price moves about 0.3% in a typical session — among the calmest in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 0.3% |
| Stretch from the 200-day average | it is trading 85.0 daily ranges above its 200-day average price (39.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale. Read that multiple with care: this company's daily range is unusually small (about 0.3% of its price), which is what makes the multiple large — a stock trading in a narrow band near a takeover price does this | 85.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.68× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
1
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +0.51% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 0.6 percentage points (the stock gained 1.8% while the market gained 2.3%) | -0.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 0.6 percentage points (the stock gained 2.5% while the market gained 3.1%) | -0.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 58.7 percentage points (the stock gained 69.8% while the market gained 11.1%) | +58.7% |
| vs market, 12 months | over the past 12 months this stock beat the market by 27.7 percentage points (the stock gained 48.2% while the market gained 20.5%) | +27.7% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 1.9% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 0.8% of the share price, which is taken to mean a barrier that gives way easily. | +1.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 28% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $10.74 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +28.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% above the average price paid since it last reported on 2026-07-31 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $13.65 — a volume-weighted average of daily closes over 16 sessions, not a true tick-by-tick VWAP. | +0.7% |
Price levels it has turned at before
OGN last closed at $13.75 on 2026-08-21. Since 2024-08-21 it has turned at 7 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $13.39 | Support | 2.6% below the last close | turned there five times · 2025-04-29 to 2026-07-08 |
| $14.46 | Resistance | 5.2% above the last close | turned there twice · 2024-11-19 to 2025-02-07 |
| $16.02 | Resistance | 16.5% above the last close | turned there four times · 2024-12-12 to 2025-03-19 |
| $10.41 | Support | 24.3% below the last close | turned there four times · 2025-04-21 to 2025-07-30 |
| $17.16 | Resistance | 24.8% above the last close | turned there twice · 2024-10-24 to 2025-02-13 |
| $9.99 | Support | 27.3% below the last close | turned there twice · 2025-09-25 to 2026-01-23 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Overbought (14-day RSI above 70) · Near the 52-week high · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (3.20 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$11.25 range $8.00 – $14.00; median $11.50
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for OGN
- Consensus EPS estimate$1.05 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on specific established brands and biosimilar products for revenue.","Exposure to intense competition in the pharmaceutical industry and risks related to licensing and trademark ownership.","Financial risks associated with long-term debt and the impact of currency exchange fluctuations."]
What changed in the latest 10-Q
AI-assisted comparison of OGN's 10-Q filed 2026-05-04 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to pending merger with Sun Pharmaceutical Industries and associated risks (timing, stockholder approval, competing offers, regulatory approvals, termination fee, management distraction, stockholder litigation, business opportunity restrictions, stock price impact, merger benefits realization) in newer filing
- Added 'possible,' 'probable,' 'outcome,' 'likely,' 'could,' and 'target' to list of forward-looking statement indicator words in newer filing
- Added reference to ability to hire/retain permanent CEO and other key employees in newer filing
- Added 'global events, such as regional conflicts in the Middle East and elsewhere' in newer filing
- Added reference to 'volatile market conditions, and instability in the global banking system' in newer filing
- Removed:
- Removed reference to 'Audit Committee investigation described in our Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission (the "SEC") on October 27, 2025' from newer filing
- Removed reference to 'leadership changes announced in the Form 8-K, including the risk that appointing a new Chief Executive Officer may take longer than anticipated' from newer filing
- Removed 'potential' and 'should' from the standalone list of forward-looking indicator words in newer filing (though 'should' still appears in phrase)
- Removed reference to 'unfavorable publicity and media reports' in newer filing
- Removed reference to 'potential impact that actions by activist stockholders could have on the pursuit of our business strategies' from newer filing
- Removed reference to 'loss of key personnel or highly skilled employees' as standalone item in newer filing
- Removed reference to 'market volatility, downgrades to the U.S. government's sovereign credit rating or its perceived creditworthiness, changing political or geopolitical conditions, market contraction, boycotts, and sanctions' in newer filing
- Removed reference to 'difficulties with performance of third parties we rely on for our business growth' from newer filing
- Removed reference to 'continued impact of the September 2024 loss of exclusivity ("LOE") for Atozet™1 (ezetimibe and atorvastatin)' in newer filing
- Removed reference to 'difficulties and uncertainties inherent in the implementation of our acquisition strategy or failure to recognize the benefits of such acquisitions' from newer filing
- Removed reference to 'antitrust litigation' and 'including tax disputes, environmental claims' from legal factors section in newer filing
- Reworded:
- Changed 'economic factors over which we have no control, including changes in inflation, interest rates, recessionary pressures, and foreign currency exchange rates' to 'the impact of global business, political and macroeconomic conditions, including inflation, interest rate fluctuations, recessionary pressures, foreign currency exchange rates, volatile market conditions, and instability in the global banking system' in newer filing
- Changed 'uncertainties surrounding the Audit Committee investigation' language to introductory language about pending merger risks in newer filing
- Changed 'the U.S. Securities and Exchange Commission ("SEC")' to simply 'the SEC' in newer filing
- Changed 'U.S. and comparable government agencies' to 'U.S. and comparable foreign government agencies' in newer filing
- Changed reference from 'Organon & Co. ("Organon," the "Company," "we," "our," or "us")' company names to simplified references in newer filing
- Changed 'health care' (two words) to 'healthcare' (one word) in newer filing
- Changed 'legal factors, such as product liability claims, stockholder litigation, governmental investigations, and patent disputes' (removing antitrust and tax references) in newer filing
- Notes:
- The newer filing text appears truncated at the end; comparison is limited to the text provided
- The older filing text also appears truncated; full extent of all changes may not be captured
- References to specific company names and formatting may have subtle variations not fully captured in this comparison
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($200307) — 1 selling insider
- Last 90 days0 buys · 1 sell ($200307) — 1 selling insider
- Last 180 days1 buy ($353080) · 2 sells ($553387) — 1 buying, 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-05. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about OGN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding OGN as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 47,757,067
- Reported value $286,064,830
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
OGN had 16,806,674 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
OGN had 6.40% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.19 days to cover at the same settlement.
- Reported short interest (shares) 16,806,674
- Short interest (% of shares outstanding) 6.40%
- Prior settlement (shares) 16,243,541
- Reported change 3.47%
- Days to cover (reported) 6.19
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- AbbVie (ABBV)
- Amgen (AMGN)
- Eli Lilly (LLY)
- Janssen Biotech (JNJ)
- Genentech (ROG)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare OGN vs…
Frequently asked questions
What does Organon & Co. (OGN) do?
Organon & Co. is a global healthcare company focused on developing and delivering health solutions through a portfolio of medicines and treatments. The company's business is structured around three primary pillars: women's health, biosimilars, and established brands.
What sector is Organon & Co. (OGN) in?
Organon & Co. (OGN) is classified in the Health Care sector. Its industry is pharmaceuticals. It trades on NYSE.
Does OGN pay a dividend?
Yes — Organon & Co. (OGN) pays a dividend, with an indicated yield of about 9.86% and 1-year non-decreasing per-share dividend streak (SEC EDGAR XBRL) (market data, as of 2026-08-24). Informational only — not financial advice.
Who are Organon & Co.'s (OGN) competitors?
Notable peers of Organon & Co. (OGN) include AbbVie, Amgen, Eli Lilly, Janssen Biotech and Genentech. This peer set is informational only — not financial advice.
Is Organon & Co. (OGN) overbought or oversold right now?
Organon & Co. (OGN) is currently in overbought territory (its 14-day RSI is 74, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on OGN come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.